 | |
| Type | Subsidiary |
|---|---|
| Industry | Bioelectronics |
| Founded | November 2016[1] |
| Founders | [2] |
| Headquarters | , |
Key people | Kristoffer Famm (President)[4] |
| Parent | GlaxoSmithKline (55% equity interest)[3] |
| Website | galvani |
Galvani Bioelectronics is a Stevenage, United Kingdom-based[5] bioelectronics R&D company.
History[edit]
It was founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][2] The partnership to form the company was announced on 1 August 2016.[3]
Verily has a 45% equity interest, while GSK has a 55% equity interest, making GSK the effective owner.[3] The initial agreed upon investment between the two companies is up to £540 million over a period of seven years[3][6] and will be used "to develop prototype devices aimed at controlling a variety of chronic conditions."[7] Additionally, both companies agreed to contribute their existing intellectual property rights.
References[edit]
- ^ a b c "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
- ^ a b "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
- ^ a b c d e Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired. Retrieved 24 December 2016.
- ^ "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
- ^ Kollewe, Julia (28 August 2017). "Electroceuticals: the 'bonkers' gamble that could pay off for GlaxoSmithKline". the Guardian. Retrieved 3 August 2018.
- ^ "Bioelectric Medicine Market Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future". Worldanalytics24.com. 23 January 2019. Retrieved 31 January 2019.
- ^ "Galvani Bioelectronics". FierceBiotech. Retrieved 13 July 2020.
External links[edit]
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |